TSO3 Inc

TSO3 — Investor Presentation (February 2016)

28 slides from TSO3's investor presentation, February 2016

  1. Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing

    TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation February 2016

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD TSX:TOS Stock Price2 (2/15/16) US$1.26 Total Revenue (ttm) $1.2M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low2 $1.63 -$0.82 Net Income (ttm) $(5.1)M Avg. Daily Vol. (3 mo.) 291K • High-margin consumables and EPS (ttm) $(0.06) maintenance offer su

  4. Slide 4: TSO3 - Who We Are

    TSO3 - Who We Are TSX:TOS  An industry Innovator in medical device sterilization  FDA-cleared low temperature sterilization system with breakthroughs in capabilities, effectiveness and cost Global Distribution Partner  Razor/Razorblade business model: proprietary consumables create high-margin re

  5. Slide 5: Large Target Market

    Large Target Market TSX:TOS Global Sterilization Equipment Market1  Global sterilization equipment market is expected grow ($ billions) at a 7.6% CAGR to $6.1 billion by 20201  Market segmented into equipment, consumables and $6.1B accessories, and contract sterilization services $5.7B $5.3B  Con

  6. Slide 6: Key Market Driver: Demographics

    Key Market Driver: Demographics TSX:TOS  Global population is aging Aging U.S. Population Expected to  U.S. 65+ age group to grow 35%, from 40 million in 2010 to 54 million by 20201 Drive Growth in MIS Surgical  Globally, 65+ to grow >100% by 20202 Services  Patients age 65+ currently consume 50

  7. Slide 7: MIS Device and Endoscope Use - Increasing the Need for Low-Temperature Sterilization

    MIS Device and Endoscope Use - Increasing the Need for Low-Temperature Sterilization TSX:TOS  30 million+ Minimally Invasive Surgery (MIS) operations annually in U.S. and growing  700,000 ERCP procedures annually in the U.S.1  2 million colonoscopies annually in the U.S. 1  MIS benefits are driv

  8. Slide 8: The Problem with Disinfection-only: Superbug & Endoscope Connection

    The Problem with Disinfection-only: Superbug & Endoscope Connection TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  At least 2 million Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1  Half of all bugs that cause infections after surgery are antibiotic resistant2

  9. Slide 9: Effective Medical Device Reprocessing is Critical to Reducing CRE Infections

    Effective Medical Device Reprocessing is Critical to Reducing CRE Infections TSX:TOS  Use of non-sterile devices contributes to increased Medical Reprocessing Lifecycle infection rates and hospital stays  Therefore sterilization of reusable medical devices is an essential element for positive surg

  10. Slide 10: Important Regulatory Growth Driver

    Important Regulatory Growth Driver TSX:TOS  FDA has recently identified flexible endoscopes as known source of infection and cause of death  FDA has recorded 109 reports of infections or contamination related to bronchoscopes over the FDA safety communication: past five years, including 50 in 2014

  11. Slide 11: Our Answer to these Issues and Challenges?

    Our Answer to these Issues and Challenges? TSX:TOS The FDA-Cleared, STERIZONE® VP4 Sterilizer - Dual Sterilant, Low Temperature Sterilization System - Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, fewer Proprietary Software automatically operator errors due to error fre

  12. Slide 12: STERIZONE VP4 Sterilizer Features

    STERIZONE® VP4 Sterilizer Features TSX:TOS  Broadest global regulatory claims of any sterilizer  Only FDA-cleared sterilizer utilizing dual sterilants (Hydrogen Peroxide and Ozone)  Only new generation sterilizer with validated claims for colonoscopes, gastroscopes, and duodenoscopes (Canada and

  13. Slide 13: Competitive Landscape

    Competitive Landscape TSX:TOS Ethelyne Oxide Hydrogen Peroxide Hydrogen Peroxide Hydrogen Peroxide + Ozone Technology (ETO) (H2O2) (H2O2) (H2O2/O3) Cycle Mass n/a Up to 21 lb Up to 25 lb Up to 75 lb Cycle Times 18-23 hours 21-56 mins 24-60 mins 46 mins Device moderate Low Low High Processing Flexibi

  14. Slide 14: Extensive Global Patent Portfolio Creates Competitive Barriers

    Extensive Global Patent Portfolio Creates Competitive Barriers TSX:TOS  Broad global patent coverage Our Global Patent Portfolio  TSO3 sterilization method; selective Projected1 Submitted Granted control of condensation  Use of its Dynamic Sterilant Delivery U.S. 1 8 6 System™ using the two steri

  15. Slide 15: Partnering with Getinge for Global Sales and Service

    Our Go-to-Market Strategy: Partnering with Getinge for Global Sales and Service TSX:TOS Getinge Global Presence  USA  Czech  Getinge Infection Control (part of Getinge Group)  Canada Republic  Turkey  Top global provider of infection control devices  UK  Associates: 3,089  China  France 

  16. Slide 16: Exclusive Global Distribution Agreement

    TSO3 and Getinge Exclusive Global Distribution Agreement TSX:TOS  Q4 2015 - Getinge granted exclusive global distributor rights to STERIZONE® VP4 Sterilizer “The STERIZONE® VP4 Sterilizer uniquely addresses an unmet global  US$7.5M license fee paid to TSO3 in Q4 2015 need for cost effective, high

  17. Slide 17: Getinge Sales Target for TSO3 STERIZONE VP4 Sterilizer

    Getinge Sales Target for TSO3 STERIZONE® VP4 Sterilizer TSX:TOS  Getinge’s commitment: • Reflects unit deployments only 300+  >10% of the ~3,000 unit/US$450 million units1 • Higher-margin consumables annual global replacement market within and accessories are additional five years = 300+ units/yea

  18. Slide 18: Recent Financials and Outlook

    Recent Financials and Outlook All Dollars in USD TSX:TOS Total Revenue (ttm) $1.2M 2015 Quarterly Revenue Growth Annual Revenue Net Income (ttm) $(5.1)M ($ Millions) Revenue Growth EPS (ttm)¹ $(0.06) $0.90 ($ Millions) Cash & Short-term Investments2,3 $23.7M M Monthly Burn Rate ~$700K Total Assets (

  19. Slide 19: Growth Strategies

    Growth Strategies TSX:TOS  Support Getinge for global introduction and commercialization of STERIZONE® VP4 Sterilizer  Broaden product portfolio with development and commercialization of new products:  Purpose-built or sterilizer products  Iterations of existing systems for local market adoption

  20. Slide 20: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  STERIZONE® VP4 Sterilizer: FDA-cleared medical device sterilization system with multiple breakthroughs in design, capability, effectiveness and operational cost  Exclusive, performance-based global distribution agreement with Getinge: minimum sales commitment affirms ma

  21. Slide 21: Contact Us

    Contact Us TSX:TOS TSO3 Inc. - Canada Investor Relations 2505, avenue Dalton Québec, Québec Liolios Group, Inc. G1P 3S5 CANADA Ron Both, Senior Managing Director Tel (949) 574-3860 Tel (418) 651-0003 TOS@liolios.com info@tso3.com Renmark Financial Communications Inc. TSO3 Corporation - USA Barry Mir

  22. Slide 22: Appendix

    Appendix +,

  23. Slide 23: Evolution of TSO3 - From Development Stage to Major Commercial Rollout

    Evolution of TSO3 – From Development Stage to Major Commercial Rollout TSX:TOS 2000 2009 2010 2015 2015 2015 2015 125L Ozone Sterilizer Health Canada Received CE Mark Completed Additional Established Allowed received regulatory licenses notice of conformity CN$11.5 million patent first U.S. expanded

  24. Slide 24: Senior Leadership

    Senior Leadership TSX:TOS Richard Rumble, President and CEO Glen Kayll, Chief Financial Officer • President, CEO and director of TSO3 since October 2008 • Appointed CFO December 2015 • 25 years of experience in N. American and global medical device • Brings 20+ years of senior management experience,

  25. Slide 25: Board of Directors

    Board of Directors TSX:TOS Richard Rumble | Director Germain Carriere | Chairman • Chairman since June 1998. • In recent years, after holding the position of Vice Chairman, Corporate Strategy, at National Bank Financial Inc., he held the positions of President and Chief Operating Officer at Desjardi

  26. Slide 26: Board of Directors (Cont'd)

    Board of Directors (Cont’d) TSX:TOS Claude Michaud | Director • Joined TSO3 board in March 2013. • Brings to the board his expertise in corporate finance, mergers and acquisitions and corporate development. • Experienced finance executive and investment banker. 15-year career in investment banking w

  27. Slide 27: FDA Links Superbug to Key Medical Device

    FDA Links Superbug to Key Medical Device TSX:TOS FDA links "superbug" to key medical device On Thursday, the U.S. Food and Drug Administration issued an advisory warning doctors that even when a manufacturer's cleaning instructions are followed, infectious germs may linger in the devices. Advisory:

  28. Slide 28: Evolution of Classification of Reprocessing Requirements

    Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements TSX:TOS  Since multi-channeled flexible Body Reprocessing FDA Device Class endoscopes, including Highest Contact Requirements Today Signaled colonoscopes and duodenoscopes are typically Sterile Body

TSO3 — Investor Presentation (February 2016) on 6ix